Occam Places CFO for Prominent Swiss Biotech Alentis
.jpg)
In August 2024, Occam Global placed Jonathan Freve as Chief Financial Officer (CFO) of Alentis Therapeutics, a Jeito Capital, Novo Holdings, RA Capital, Bpifrance, and Schroders Capital investment.
Jon brings to Alentis over 20 years of financial experience in increasingly senior roles in the biotechnology sector. Most recently, he served as the CFO of Galecto, where he was responsible for leading financial operations, investor relations, and fundraising efforts. Before his role at Galecto, Jon was the CFO of Spring Bank Pharmaceuticals and held Corporate Controller positions at other publicly traded global companies.
Jon is a CPA who has worked on several successful initial public offerings, secondary offerings, mergers, and acquisitions. He holds a Bachelor’s degree in Business Administration from the University of Massachusetts Amherst.
Occam Global is a biotech executive search, recruiting, and leadership advisory firm with specialties across technological fields, including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build biotech executive leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.